AiCuris supports the state of North Rhine-Westphalia with the COVID-19 fight against outbreaks in slaughterhouses
^ DGAP-News: AiCuris Anti-infective Cures GmbH / Key word (s): Sustainability AiCuris supports the state of North Rhine-Westphalia in fighting COVID-19 outbreaks in slaughterhouses
15.05.2020 / 09:00 The issuer / publisher is responsible for the content of this announcement.
AiCuris supports the state of North Rhine-Westphalia with the COVID-19 fight against outbreaks in slaughterhouses
* After the frequent occurrence of coronavirus infections among employees of a slaughterhouse in Coesfeld, all of the approximately 20,000 employees and contract workers of the slaughterhouses in NRW are currently being tested
* AiCuris has been involved at multiple levels since the pandemic broke out and has established and deployed SARS-CoV-2 test capabilities at short notice to help combat the corona pandemic
WUPPERTAL, Germany, May 15, 2020 – AiCuris Anti-infective Cures GmbH, a leading company in the research and development of medicinal products for infectious diseases, supports the state of North Rhine-Westphalia (NRW) in testing the people working in slaughterhouses for the SARS coronavirus. CoV-2.
The testing of all employees of slaughterhouses serves to identify possible sources of infection or is intended to help fight outbreaks. In addition to the country’s four chemical and veterinary inspection offices, AiCuris is involved in carrying out the approximately 20,000 tests.
At the beginning of the pandemic, AiCuris had offered its support as an expert in the field of infection research and had agreed to provide test capacities at the request of the state of North Rhine-Westphalia. In addition, the company has been involved in support measures in association with local hospitals and health institutions for some time. For the testing of larger population groups, specific SARS-CoV-2 test capacities have now been set up and established at short notice.
“We are pleased to be able to contribute with our expertise not only through the investigation of selected proprietary substances to the identification of a possible active substance against SARS-CoV-2, but also to provide our Land NRW with specific and immediate support in this situation at short notice,” said Dr . Holger Zimmermann, scientific director of AiCuris. “Projects like this are essential to advance the clarification of the corona infection chains, to quickly identify outbreaks and to prevent further spreads. We are happy to make our contribution here and support the country in this situation.”
“The outbreak in Coesfeld shows that we have by no means defeated the insidious virus. It is now all the more important that the country, its citizens and its companies pull together. The more valuable is the use of AiCuris for which I am I would like to thank you, “said North Rhine-Westphalia Health Minister Karl-Josef Laumann.
The state of North Rhine-Westphalia was the first federal state to implement an emergency mechanism
After the frequent occurrence of coronavirus infections in a slaughterhouse in Coesfeld, NRW decided to test the approx. 20,000 employees and contract workers of all slaughterhouses across the country. Such measures are currently one of the most important means in the fight against the virus. A quick diagnosis helps to quickly quarantine infected employees and thus prevent other people from becoming infected. In order to support hospitals, practices and test stations in difficult situations, the state of North Rhine-Westphalia endeavors to integrate available capacities for tests for SARS-CoV-2 infections. With its expertise, its contacts and laboratories, AiCuris supports clinics in the region and the Minister of Health in NRW in the field of diagnostics, thereby helping to fill gaps in supply and capacity.
About AiCuris Anti-infective Cures GmbH AiCuris was founded in 2006 as a spin-off from Bayer AG and focuses on the research and development of active substances against infectious diseases. The company’s main investors are Dres. Strüngmann. With PREVYMIS (TM) (Letermovir), a “first-in-class” non-nucleoside cytomegalovirus (CMV) inhibitor has been developed, which works by a new mechanism of action. It was licensed to MSD in 2012 and has received marketing approval in the EU, the United States, Japan and other parts of the world for the prevention of CMV infections in adult recipients of allogeneic hematopoietic stem cell transplantation (HSCT). The company is developing other drugs for viruses such as herpes simplex virus (HSV), hepatitis B virus (HBV) and adenoviruses. In the field of antibacterial agents, AiCuris focuses on the research of innovative treatment options against life-threatening (multi-) resistant hospital pathogens.
In November 2018 Prof. Dr. Helga Rübsamen-Schaeff, founding CEO, and Dr. Holger Zimmermann, CEO of AiCuris, was awarded the German Future Prize 2018 for the development of letermovir and her project “Protection in the absence of an immune system – the life-saving innovation against dangerous viruses”.
More information about the company can be found at www.aicuris.com. Follow us on LinkedIn.
Contact:
Company contact: Media contact:
AiCuris Anti-infective Cures GmbH MC Services AG
Katja Woestenhemke Dr. Solveigh Mähler Phone: +49 202 317 63 0 Phone: +49 211 529 252 19 Email: [1][email protected] email: [1][email protected]
1. mailto: [email protected] 1. mailto: [email protected]
15.05.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer / publisher is responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial / Corporate News and Press Releases. Media archive at http://www.dgap.de
1046031 15.05.2020
°
– .
